EP2348101A2 - Corynebacterium genus microorganism having ability to produce n-acetyl glucosamine and method for producing n-acetyl glucosamine or glucosamine using same - Google Patents
Corynebacterium genus microorganism having ability to produce n-acetyl glucosamine and method for producing n-acetyl glucosamine or glucosamine using same Download PDFInfo
- Publication number
- EP2348101A2 EP2348101A2 EP09822192A EP09822192A EP2348101A2 EP 2348101 A2 EP2348101 A2 EP 2348101A2 EP 09822192 A EP09822192 A EP 09822192A EP 09822192 A EP09822192 A EP 09822192A EP 2348101 A2 EP2348101 A2 EP 2348101A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- glucosamine
- microorganism
- acetyl glucosamine
- acetyl
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 title claims abstract description 57
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 title claims abstract description 57
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 title claims abstract description 57
- 229950006780 n-acetylglucosamine Drugs 0.000 title claims abstract description 57
- 244000005700 microbiome Species 0.000 title claims abstract description 45
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 title claims abstract description 42
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 229960002442 glucosamine Drugs 0.000 title claims abstract description 42
- 241000186216 Corynebacterium Species 0.000 title claims abstract description 35
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 16
- 108010043841 Glucosamine 6-Phosphate N-Acetyltransferase Proteins 0.000 claims description 39
- 102000002740 Glucosamine 6-Phosphate N-Acetyltransferase Human genes 0.000 claims description 34
- 230000001939 inductive effect Effects 0.000 claims description 19
- 241000186226 Corynebacterium glutamicum Species 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 108010022717 glucosamine-6-phosphate isomerase Proteins 0.000 claims description 13
- 102100041034 Glucosamine-6-phosphate isomerase 1 Human genes 0.000 claims description 11
- 102100033238 Elongation factor Tu, mitochondrial Human genes 0.000 claims description 8
- 101000851240 Homo sapiens Elongation factor Tu, mitochondrial Proteins 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical group 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 6
- 102000005421 acetyltransferase Human genes 0.000 abstract description 2
- 108020002494 acetyltransferase Proteins 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 24
- 239000013598 vector Substances 0.000 description 19
- BRGMHAYQAZFZDJ-PVFLNQBWSA-N N-Acetylglucosamine 6-phosphate Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BRGMHAYQAZFZDJ-PVFLNQBWSA-N 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- XHMJOUIAFHJHBW-UKFBFLRUSA-N alpha-D-glucosamine 6-phosphate Chemical compound N[C@H]1[C@@H](O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O XHMJOUIAFHJHBW-UKFBFLRUSA-N 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229920002101 Chitin Polymers 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002028 Biomass Substances 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000012136 culture method Methods 0.000 description 4
- 230000006196 deacetylation Effects 0.000 description 4
- 238000003381 deacetylation reaction Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000238421 Arthropoda Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 1
- 241001644925 Corynebacterium efficiens Species 0.000 description 1
- 241001487058 Corynebacterium efficiens YS-314 Species 0.000 description 1
- 241000337023 Corynebacterium thermoaminogenes Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 208000008555 Shellfish Hypersensitivity Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- UGEVDEPHPZWGPI-KEWYIRBNSA-N [(2R,3S,4R,5R)-6-acetyl-5-amino-3,4,6-trihydroxyoxan-2-yl]methyl dihydrogen phosphate Chemical compound P(=O)(O)(O)OC[C@@H]1[C@H]([C@@H]([C@H](C(O)(O1)C(C)=O)N)O)O UGEVDEPHPZWGPI-KEWYIRBNSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 241000319304 [Brevibacterium] flavum Species 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 101150100121 gna1 gene Proteins 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003262 industrial enzyme Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920001522 polyglycol ester Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000004336 shellfish allergy Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/15—Corynebacterium
Definitions
- the present invention relates to a genetically modified microorganism of the genus Corynebacterium producing N-acetyl glucosamine, and a method for producing N-acetyl glucosamine or glucosamine using the same.
- Glucosamine is an amino derivative of glucose
- N-acetyl glucosamine is an acetylated derivative of glucosamine. They are important constituents of many natural polysaccharides, and can form structural materials for cells, constituting the cell wall.
- N-acetyl glucosamine is an important component of protein synthesis, involved in tissue regeneration, and thus N-acetyl glucosamine has therapeutic potential in the prevention and treatment of a wide variety of diseases such as gastritis, food allergies, inflammatory bowel disease (IBD), diverticulitis, acute and chronic forms of rheumatoid arthritis and osteoarthritis, as well as the pathological conditions arising from metabolic disorders of the osteoarticular tissues.
- IBD inflammatory bowel disease
- Glucosamine is also used as a functional food applied for the prevention and treatment of human osteoarthritic diseases.
- Glucosamine is obtained by acid hydrolysis of chitin, a complex carbohydrate derived from N-acetyl glucosamine.
- chitin can also be produced by acid hydrolysis of chitosans.
- the raw material, chitin is a copolymer of N-acetyl glucosamine and glucosamine, and is a common natural substance found in arthropods and fungi.
- the chitin can be obtained from arthropod refuse (lobster, shrimp, krill, crab, and prawn exoskeletons) and more recently from inexpensive sources like fungal biomass used in citric acid production.
- glucosamine content in arthropod refuse and fungal biomass is low and thus large volumes of waste are produced.
- Glucosamine is considerably expensive because the production process itself has relatively low yield and is energy and chemically intensive.
- the common forms of glucosamine being derived from shellfish, it is known that there is the potential for allergic reactions in persons sensitive to shellfish.
- the availability of raw material e.g., a source of chitin, such as crab shells
- PCT Publication No. WO 02/66667 discloses a method of making glucosamine from microbial biomass to remove the possibility of allergic reactions. This production method overcomes problems associated with shellfish allergy, but it suffers from a major problem of low yield. More particularly, since the method relies on the biomass waste generated in fermentation of other products such as citric acid, it is not enough to produce sufficient quantities of glucosamine that meet the increasing market demand for the product.
- N-acetyl glucosamine is currently produced by the acetylation of glucosamine using an organic acetylating reagent such as acetic anhydride, but this production method requires high costs. Also, because of low production yield, it is not easy to produce N-acetyl glucosamine on a large scale.
- US Patent No. 7,332,304 discloses a method of producing N-acetyl glucosamine by E.coli fermentation. This method suggests E.coli fermentation for a high production yield of N-acetyl glucosamine which dramatically resolves the encountered problems including low production yield of N-acetyl glucosamine due to the conventional complicated process.
- glucosamine may be produced from deacetylation of N-acetyl glucosamine by simple acid treatment ( Novikov V.Y. et al. Russ. J. Appl. Chem. 1997:1467-1470 ), and thus it is also possible to produce glucosamine in a high yield.
- the inducible expression system is disadvantageous in that an inducing material is needed, leading to an increase in production costs and an induction time point should be determined, and therefore it is considered to be not suitable for industrial production by large-scale fermentation.
- the above method has a drawback of using E.coli and an inducible expression system.
- E.coli fermentation technology has been developed in order to overcome the problems of the limited availability of raw materials and low production yield.
- strains suitable for producing N-acetyl glucosamine and glucosamine, which are safe for humans and animals.
- the present inventors have developed a microorganism of the genus Corynebacterium for large-scale fermentation of N-acetyl glucosamine and glucosamine without causing environmental problems, capable of realizing production stability and industrial application, and a method for producing N-acetyl glucosamine and glucosamine using the same, thereby completing the present invention.
- the present invention relates to a microorganism of the genus Corynebacterium having an ability to produce N-acetyl glucosamine and glucosamine, in which the microorganism has a glucosamine-6-phosphate acetyltransferase activity and a reduced or deleted glucosamine-6-phosphate deaminase activity.
- glucosamine-6-phosphate acetyltransferase refers to an enzyme for producing N-acetyl glucosamine-6-phosphate from the acetylation of glucosamine-6-phosphate. This enzyme is found in the microorganisms of the genus Saccharomyces, but not in the microorganisms of the genus Corynebacterium.
- the term "having a glucosamine-6-phosphate acetyltransferase activity" or "a microorganism of the genus Corynebacterium having a glucosamine-6-phosphate acetyltransferase activity” means that the glucosamine-6-phosphate acetyltransferase gene not present in the microorganisms of the genus Corynebacterium is introduced into a microorganism of the genus Corynebacterium to express glucosamine-6-phosphate acetyltransferase, and therefore, the microorganism of the genus Corynebacterium may convert N-glucosamine-6-phosphate into N-acetyl glucosamine-6-phosphate using the enzyme.
- the method of imparting the glucosamine-6-phosphate acetyltransferase activity to the microorganism of the genus Corynebacterium by introduction of the gene may be performed by a variety of methods well known in the art.
- the glucosamine-6-phosphate acetyltransferase-encoding nucleic acid sequence is introduced into a vector, and the recombinant vector is used to transform the microorganism of the genus Corynebacterium.
- the glucosamine-6-phosphate acetyltransferase gene is any gene that has a nucleic acid sequence being operable in the microorganism of the genus Corynebacterium.
- the gene is a gene derived from Saccharomyces cerevisiae, and preferably a nucleic acid sequence of SEQ ID NO. 11.
- the glucosamine-6-phosphate acetyltransferase-encoding sequence can be modified to some degree as long as it retains its activity. It will be readily understood by those skilled in the art that the nucleic acid sequence retaining 70% or more homology by the artificial modification is equivalent to that derived from the nucleic acid sequence of the present invention, as long as it retains the gene activity desired in the present invention.
- a promoter is operably linked to the glucosamine-6-phosphate acetyltransferase gene of the present invention so as to induce expression of the gene. More preferably, with respect to the objects of the present invention, the promoter is a promoter to induce constitutive or inducible expression of glucosamine-6-phosphate acetyltransferase by the microorganism of the genus Corynebacterium, and the promoter is any gene that is able to induce constitutive or inducible expression of glucosamine-6-phoaphate acetyltransferase introduced in the microorganism of the genus Corynebacterium.
- the constitutive promoter is an EFTU promoter
- the inducible expression promoter is a laclq-Ptac promoter.
- glucosamine-6-phosphate deaminase refers to an enzyme involved in the conversion of acetyl glucosamine-6-phosphate into glucosamine-6-phosphate.
- the microorganism of the genus Corynebacterium of the present invention is characterized in that it shows less or no expression of the glucosamine-6-phosphate deaminase-encoding gene, compared to the naturally occurring gene, due to partial or total deletion/mutation in the glucosamine-6-phosphate deaminase-encoding nucleic acid sequence.
- the lower or lack of expression of the glucosamine-6-phosphate deaminase-encoding gene, compared to the naturally occurring gene, due to partial or total deletion/mutation in the glucosamine-6-phosphate deaminase-encoding nucleic acid sequence can be expressed herein as "reduction” or "deletion”.
- glucosamine-6-phosphate deaminase gene For example, a mutation may occur in the promoter and regulatory regions located upstream of the structure gene. A regulatory cassette attached in upstream of the structural gene may also execute the same functions.
- the promoter may be modified to reduce the expression, or gene translation may be regulated by reduced m-RNA stability so as to reduce the expression.
- the activity of glucosamine-6-phosphate deaminase may be reduced or deleted by replacement of a part or the whole of the gene with a deleted or mutated fragment by site-specific recombination DNA technology.
- no or less expression of the gene may be achieved by a variety of methods well known in the art, in addition to these methods.
- the term "ability to produce N-acetyl glucosamine” means that the microorganism of the genus Corynebacterium of the present invention has an ability to produce and accumulate N-acetyl glucosamine in the media in which it is cultured.
- the term “ability to produce glucosamine” refers to an ability to produce glucosamine from a material produced by microbial fermentation, and refers to an ability of the microorganism of the genus Corynebacterium of the present invention, that produces and accumulates glucosamine by deacetylation of N-acetyl glucosamine accumulated in the culture media into glucosamine, according to various methods known in the art.
- the term "microorganism having an ability to produce N-acetyl glucosamine and/or glucosamine” is a microorganism belonging to the genus Corynebacterium.
- the microorganism is Corynebacterium glutamicum (e.g., ATCC13032), Corynebacterium ammoniagenes (e.g., ATCC 6872), Brevibacterium lactofermentum (e.g., ATCC13869), Brevibacterium flavum (e.g., ATCC14067), Corynebacterium thermoaminogenes (e.g., FERM-BP1539), Corynebacterium efficiens (e.g., C.efficiens str.
- Corynebacterium glutamicum e.g., ATCC13032
- Corynebacterium ammoniagenes e.g., ATCC 6872
- Brevibacterium lactofermentum e.g., ATCC13869
- the microorganism is Corynebacterium glutamicum, and even more preferably, Corynebacterium glutamicum CJNAG1 deposited at KCCM (Korean Culture Center of Microorganisms, Eulim Buld., 361-221, Hongje-1-Dong, Seodaemun-Ku, Seoul, 120-861, Korea) on September 29, 2008 with the Accession No: KCCM10967P.
- KCCM Korean Culture Center of Microorganisms, Eulim Buld., 361-221, Hongje-1-Dong, Seodaemun-Ku, Seoul, 120-861, Korea
- the present invention relates to a method for producing N-acetyl glucosamine or glucosamine which comprises culturing the microorganism of the genus Corynebacterium having an ability to produce N-acetyl glucosamine.
- the present invention relates to a method for producing N-acetyl glucosamine or glucosamine, comprising the steps of (a) culturing the microorganisms of the genus Corynebacterium having an ability to produce N-acetyl glucosamine of the present invention and (b) collecting N-acetyl glucosamine or glucosamine produced in the culturing step.
- the above culture of the present invention can be performed by a proper medium and conditions known to those in the art. It is well understood by those in the art that the culture method can be used by easily adjusting the same, according to the selected strain.
- the culture methods include, but are not limited to batch, continuous culture and fed-batch. A variety of culture methods are described in, for example, the following reference: " Biochemical Engineering” by James M. Lee, Prentice-Hall International Editions, pp 138-176 .
- the medium used in the culture has to meet the culture conditions for a specific strain.
- the medium used in the present invention contains glucose as a main carbon source, and the medium may contain a proper amount of various carbon sources.
- the nitrogen source to be used is exemplified by such organic nitrogen sources as peptone, yeast extract, gravy, malt extract, corn steep liquor and bean flour and such inorganic nitrogen source as urea, ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate. These nitrogen sources may be used either alone or in combinations.
- the medium herein can additionally include potassium dihydrogen phosphate, dipotassium hydrogen phosphate and corresponding sodium-containing salts as a phosphate source.
- the medium also can include a metal salt such as magnesium sulfate or iron sulfate.
- amino acids, vitamins and proper precursors can be added. These mediums or precursors can be added to the culture by batch-type or continuous type.
- ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, and sulfuric acid may be properly added so as to adjust the pH of the cultures.
- Defoaming agents such as fatty acid polyglycol ester may be properly added so as to reduce the formation of foams in cultures.
- oxygen or oxygen-containing gas may be injected into the cultures.
- no gas may be injected or nitrogen, hydrogen, or carbon dioxide gas may be injected into the cultures.
- the cultures are maintained at 30 to 37°C, and preferably at 35 to 37oC.
- the cultivation may be continued until a desired amount of the desired material is obtained, and preferably for 10 to 160 hrs.
- the step of collecting and/or recovering N-acetyl glucosamine or glucosamine produced in the cultivation step of the present invention may be performed by a proper method known in the art, depending on the culturing procedures, for example, batch type, continuous type or fed-batch type, so as to collect the desired N-acetyl glucosamine or glucosamine from the culture medium.
- the present invention may further include the step of converting the collected N-acetyl glucosamine into glucosamine by deacetylation. It will be apparent to those skilled in the art that the conversion may be performed by the method widely known in the art (e.g., Novikov V.Y. et al. Russ. J. Appl. Chem. 1997:1467-1470 ).
- Example 1 Construction of N-acetyl glucosamine 6-phosphate deaminase mutant and chromosomal DNA substitution recombinant vector pDZ -nagAST
- N-acetyl glucosamine-6-phosphate deaminase-encoding nagA1 NCgl2556, SEQ ID NO. 1 which utilizes N-acetyl glucosamine-6-phosphate as a substrate was inactivated.
- the inactivation may be performed by various methods such as gene deletion or introduction of additional sequence, and in the present Example, a stop codon was inserted into the ORF (open reading frame) of the nagA1 gene to induce inactivation of gene translation.
- a genomic DNA was isolated from Corynebacterium glutamicum (ATCC13102), and PCR was performed using the genomic DNA as a template and primers of SEQ ID NOs. 2 and 3 so as to obtain N-acetyl glucosamine-6-phosphate deaminase-encoding gene ( nagA1: NCg12556).
- Each sequence of the primers used to amplify nags1 gene is as follows.
- N-acetyl glucosamine-6-phosphate deaminase mutant having a stop codon in ORF using the wild-type N-acetyl glucosamine-6-phosphate deaminase gene
- additional primers SEQ ID NOs. 4 and 5
- SEQ ID NOs. 4 and 5 were prepared to insert a stop codon between isoleucine at position 196 and alanine at position 197.
- PCR was performed using the wild-type nagA1 obtained by PCR as a template and each of the primers of SEQ ID NOs. 2 and 4 and SEQ ID NOs. 3 and 5. Two final products were a part of the nagA1, and thus had a half size thereof. These two products were simultaneously used as a template and the primers of SEQ ID NOs. 2 and 3 were used to perform PCR again. Through this procedure, genes encoding inactivated N-acetyl glucosamine 6-phosphate deaminase mutants were obtained.
- the inactivated nagA1 gene fragment was introduced into a chromosomal DNA substitution vector pDZ using the restriction enzymes, EcoRI (New England Biolabs, Beverly, MA) and XbaI (New England Biolabs, Beverly, MA) by the molecular biology technique disclosed in Korean Patent Publication No. 2008-0025355 , so as to construct a pDZ-nagA1ST vector ( FIG. 2 ).
- Example 3 Construction of constitutive expression vector of glucosamine-6-phosphate acetyltransferase
- glucosamine-6-phosphate acetyltransferase which is an enzyme producing N-acetyl glucosamine-6-phosphate using glucosamine-6-phosphate as a substrate
- a constitutive promoter was used to construct the vector so as to ensure constitutive expression of the enzyme during cell growth.
- the enzyme used for the expression was GNA1, the known glucosamine-6-phosphate acetyltransferase gene of yeast Saccharomyces cerevisiae.
- an EFTU promoter ( Judith B. et al. Appl Environ Microbiol. 2005:8587-8596 .) that is known as a constitutive promoter in Corynebacterium glutamicum was used. PCR was performed using the chromosome isolated from Corynebacterium glutamicum as a template and the primers of SEQ ID NOs. 6 and 7 to obtain the EFTU promoter (SEQ ID NO. 8). The obtained PCR product of EFTU promoter was introduced into a pECCG1117 vector ( Biotechnology letters vol 13, No.10, p.721-726(1991 ) or Korean Patent Publication No.
- the constructed vector was designated pECCG117-PEFTU.
- PCR was performed using the chromosome isolated from Saccharomyces cerevisiae as a template and the primers of SEQ ID NOs. 9 and 10 to obtain GNA1 (SEQ ID NO. 11).
- the obtained GNA1 was introduced into the pECCG117-PEFTU vector using SpeI (New England Biolabs, Beverly, MA) and XbaI (New England Biolabs, Beverly, MA) to construct a pECCG117-PEFTU-GNA1 vector ( FIG. 3 ).
- Each sequence of the primers used to amplify the EFTU promoter and GNA1 gene is as follows.
- Example 4 Construction of inducible expression vector of glucosamine-6-phosphate acetyltransferase
- PCR was performed using the chromosome isolated from Saccharomyces cerevisiae as a template and the primers of SEQ ID NOs. 9 and 10 to obtain GNA1.
- the obtained GNA1 was introduced into a pVWEx2 vector known as an inducible expression system in Corynebacterium glutamicum ( Appl. Microbiol. Biotechnol. 2007. 76:545-552 ) using PstI (New England Biolabs, Beverly, MA) and XbaI (New England Biolabs, Beverly, MA) to construct a pVWEx2-GNA1 vector ( FIG. 4 ).
- a lacIq-Ptac promoter was used for the inducible expression.
- Each sequence of the used primers is as follows.
- Example 5 Production of N-acetyl glucosamine using GNA1-introduced Corynebacterium glutamicum CJNAGKO
- glucosamine-6-phosphate acetyltransferase was introduced into the mutant CJNAGKO which has a stop codon in the N-acetyl glucosamine-6-phosphate deaminase (nagA1) ORF on the chromosome.
- each of p117-PEFTU-GNA1 and pVWEx2-GNA1 constructed in Examples 3 and 4 was transformed into CJNAGKO to prepare strains that have a glucosamine-6-phosphate acetyltransferase (GNA1) activity without N-acetyl glucosamine-6-phosphate deaminase activity.
- the prepared strains are designated CJNAG1 (KCCM10967P) and CJNAG2, respectively (Table 1).
- the medium composition and culture method were as follows. 5 ml of seed medium (5 g of trypton, 2.5 g of yeast extract, 5 g of NaCl, 18.5 g of Brain heart infusion in 500 ml of distilled water, and 91 g of sorbitol in 500 ml of distilled water, each of them were sterilized at high pressure and high temperature, and then mixed with each other) was put in test tubes, and then test strains were inoculated thereto, followed by incubation at 30°C for 12 hrs.
- 20 ml of the culture media (based on 1 L of distilled water, 90 g of glucose sterilized separately, 40 g of (NH 4 ) 2 SO 4 , 2.5 g of Soy Protein, 5 g of Corn Steep Solids, 3 g of urea, 1 g of KH 2 PO 4 , 0.5 g of MgSO 4 7H 2 O, 100 ⁇ g of biotin, 1000 ⁇ g of thiamine hydrochloride, 2000 ⁇ g of calcium pantothenate, 3000 ⁇ g of nicotinamide, 30 g of CaCO 3 sterilized separately) was aliquoted in 250 ml Erlenmeyer flasks, and then 200 ul of seed culture medium was inoculated thereto, followed by fermentation at 30°C for 42 hrs.
- Glucosamine can be produced from deacetylation of the produced N-acetyl glucosamine by acid treatment, which can be performed by the known method described in Novikov V.Y. et al. (Russ. J. Appl. Chem. 1997:1467-1470 ), indicating that the production of N-acetyl glucosamine easily allows additional production of glucosamine.
- a microorganism of the genus Corynebacterium having an ability to produce N-acetyl glucosamine can be developed, and thus N-acetyl glucosamine or glucosamine is produced using the microorganism, thereby realizing mass production of N-acetyl glucosamine and glucosamine without the risk of allergic reactions. Further, it is industrially applicable, since health foods and therapeutic materials can be safely produced, and crucial enzymes can be constitutively expressed.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
- The present invention relates to a genetically modified microorganism of the genus Corynebacterium producing N-acetyl glucosamine, and a method for producing N-acetyl glucosamine or glucosamine using the same.
- Glucosamine is an amino derivative of glucose, and N-acetyl glucosamine is an acetylated derivative of glucosamine. They are important constituents of many natural polysaccharides, and can form structural materials for cells, constituting the cell wall.
- N-acetyl glucosamine is an important component of protein synthesis, involved in tissue regeneration, and thus N-acetyl glucosamine has therapeutic potential in the prevention and treatment of a wide variety of diseases such as gastritis, food allergies, inflammatory bowel disease (IBD), diverticulitis, acute and chronic forms of rheumatoid arthritis and osteoarthritis, as well as the pathological conditions arising from metabolic disorders of the osteoarticular tissues. Glucosamine is also used as a functional food applied for the prevention and treatment of human osteoarthritic diseases.
- Glucosamine is obtained by acid hydrolysis of chitin, a complex carbohydrate derived from N-acetyl glucosamine. Alternatively, glucosamine can also be produced by acid hydrolysis of chitosans. The raw material, chitin is a copolymer of N-acetyl glucosamine and glucosamine, and is a common natural substance found in arthropods and fungi. The chitin can be obtained from arthropod refuse (lobster, shrimp, krill, crab, and prawn exoskeletons) and more recently from inexpensive sources like fungal biomass used in citric acid production.
- Common industrial practice is to purify the chitin by treating it with combinations of acids and bases to remove other impurities accompanying minerals, proteins, etc., and then to depolymerize and deacetylate the chitin in a single step into glucosamine through the use of concentrated hydrochloric acid in low yields at high temperature for a long time. Glucosamine as a free base is very unstable and subject to degradation. Consequently, stable salts such as hydrochloride are produced.
- The glucosamine content in arthropod refuse and fungal biomass is low and thus large volumes of waste are produced. Glucosamine is considerably expensive because the production process itself has relatively low yield and is energy and chemically intensive. In addition, with the common forms of glucosamine, being derived from shellfish, it is known that there is the potential for allergic reactions in persons sensitive to shellfish. Moreover, the availability of raw material (e.g., a source of chitin, such as crab shells) becomes gradually limited. Therefore, there is a need for a cost-effective method for producing glucosamine and N-acetyl glucosamine in high yields for commercial sale and use.
-
PCT Publication No. WO 02/66667 - Meanwhile, N-acetyl glucosamine is currently produced by the acetylation of glucosamine using an organic acetylating reagent such as acetic anhydride, but this production method requires high costs. Also, because of low production yield, it is not easy to produce N-acetyl glucosamine on a large scale.
- To overcome these problems,
US Patent No. 7,332,304 discloses a method of producing N-acetyl glucosamine by E.coli fermentation. This method suggests E.coli fermentation for a high production yield of N-acetyl glucosamine which dramatically resolves the encountered problems including low production yield of N-acetyl glucosamine due to the conventional complicated process. In addition, it is known that glucosamine may be produced from deacetylation of N-acetyl glucosamine by simple acid treatment (Novikov V.Y. et al. Russ. J. Appl. Chem. 1997:1467-1470), and thus it is also possible to produce glucosamine in a high yield. - However, this method is not suitable for the production of health foods, because the use of E.coli generates potentially toxic endotoxins. In addition, glucosamine-6-phosphate acetyltransferase, essential for the production of N-acetyl glucosamine (see
FIG. 1 : GNA1), does not exist in E.coli, and thus other microorganisms such as yeast should be introduced. There is a limitation in that expression of the crucial enzyme requires an inducible expression system (Deng M.D. et al. Met Eng. 2005:201-214). Unregulated expression of the crucial enzyme causes severe inhibition of cell proliferation. The inducible expression system is disadvantageous in that an inducing material is needed, leading to an increase in production costs and an induction time point should be determined, and therefore it is considered to be not suitable for industrial production by large-scale fermentation. In terms of safety of production and possibility of industrial adaptation, the above method has a drawback of using E.coli and an inducible expression system. - Until now, E.coli fermentation technology has been developed in order to overcome the problems of the limited availability of raw materials and low production yield. However, there have been no strains, suitable for producing N-acetyl glucosamine and glucosamine, which are safe for humans and animals. Further, there have been no reports of a producing strain that utilizes a constitutive expression system other than an inducible expression system to facilitate industrial enzyme production.
- In order to solve the above problems, the present inventors have developed a microorganism of the genus Corynebacterium for large-scale fermentation of N-acetyl glucosamine and glucosamine without causing environmental problems, capable of realizing production stability and industrial application, and a method for producing N-acetyl glucosamine and glucosamine using the same, thereby completing the present invention.
- It is an object of the present invention to provide a genetically modified microorganism of the genus Corynebacterium producing N-acetyl glucosamine, and preferably a microorganism of the genus Corynebacterium having glucosamine-6-phosphate acetyltransferase activity and reduced or deleted glucosamine-6-phosphate deaminase activity.
- It is another object of the present invention to provide a method for producing N-acetyl glucosamine or glucosamine using the microorganism of the genus Corynebacterium.
-
-
FIG. 1 illustrates N-acetyl glucosamine biosynthetic pathway and gene modification in N-acetyl glucosamine-producing strain, in which nagA is inactivated and a foreign gene GNA1 is amplified; -
FIG. 2 illustrates a structure of pDZ-nagA1ST vector, in which nagA1 having a stop codon is cloned into pDZ; -
FIG. 3 illustrates a structure of pECCG117-PEFTU-GNAl vector, in which the constitutive expression promoter PEFTU is primarily cloned into a pECCG117 vector, and GNA1 is additionally cloned thereto; and -
FIG. 4 illustrates a structure of pVWEx2-GNA1 vector, in which GNA1 is cloned into a pVWEx2 vector. - In one aspect, the present invention relates to a microorganism of the genus Corynebacterium having an ability to produce N-acetyl glucosamine and glucosamine, in which the microorganism has a glucosamine-6-phosphate acetyltransferase activity and a reduced or deleted glucosamine-6-phosphate deaminase activity.
- In the present invention, glucosamine-6-phosphate acetyltransferase refers to an enzyme for producing N-acetyl glucosamine-6-phosphate from the acetylation of glucosamine-6-phosphate. This enzyme is found in the microorganisms of the genus Saccharomyces, but not in the microorganisms of the genus Corynebacterium.
- As used herein, the term "having a glucosamine-6-phosphate acetyltransferase activity" or "a microorganism of the genus Corynebacterium having a glucosamine-6-phosphate acetyltransferase activity" means that the glucosamine-6-phosphate acetyltransferase gene not present in the microorganisms of the genus Corynebacterium is introduced into a microorganism of the genus Corynebacterium to express glucosamine-6-phosphate acetyltransferase, and therefore, the microorganism of the genus Corynebacterium may convert N-glucosamine-6-phosphate into N-acetyl glucosamine-6-phosphate using the enzyme.
- The method of imparting the glucosamine-6-phosphate acetyltransferase activity to the microorganism of the genus Corynebacterium by introduction of the gene may be performed by a variety of methods well known in the art. In the specific embodiment of the present invention, the glucosamine-6-phosphate acetyltransferase-encoding nucleic acid sequence is introduced into a vector, and the recombinant vector is used to transform the microorganism of the genus Corynebacterium.
- The glucosamine-6-phosphate acetyltransferase gene is any gene that has a nucleic acid sequence being operable in the microorganism of the genus Corynebacterium. In one specific embodiment, the gene is a gene derived from Saccharomyces cerevisiae, and preferably a nucleic acid sequence of SEQ ID NO. 11. In particular, the glucosamine-6-phosphate acetyltransferase-encoding sequence can be modified to some degree as long as it retains its activity. It will be readily understood by those skilled in the art that the nucleic acid sequence retaining 70% or more homology by the artificial modification is equivalent to that derived from the nucleic acid sequence of the present invention, as long as it retains the gene activity desired in the present invention.
- Preferably, a promoter is operably linked to the glucosamine-6-phosphate acetyltransferase gene of the present invention so as to induce expression of the gene. More preferably, with respect to the objects of the present invention, the promoter is a promoter to induce constitutive or inducible expression of glucosamine-6-phosphate acetyltransferase by the microorganism of the genus Corynebacterium, and the promoter is any gene that is able to induce constitutive or inducible expression of glucosamine-6-phoaphate acetyltransferase introduced in the microorganism of the genus Corynebacterium. In one specific embodiment, the constitutive promoter is an EFTU promoter, and the inducible expression promoter is a laclq-Ptac promoter. When the expression of glucosamine-6-phosphate acetyltransferase in E.coli is induced at an early stage of growth, severe growth inhibition occurs, and thus an inducible expression system should be used only (Deng M.D. et al. Met Eng. 2005:201-214). On the contrary, the microorganism of the genus Corynebacterium of the present invention has an advantage that its growth is not affected by the inducible or constitutive expression of the enzyme.
- As used herein, the term "glucosamine-6-phosphate deaminase" refers to an enzyme involved in the conversion of acetyl glucosamine-6-phosphate into glucosamine-6-phosphate. For the objects of the present invention, the microorganism of the genus Corynebacterium of the present invention is characterized in that it shows less or no expression of the glucosamine-6-phosphate deaminase-encoding gene, compared to the naturally occurring gene, due to partial or total deletion/mutation in the glucosamine-6-phosphate deaminase-encoding nucleic acid sequence. The lower or lack of expression of the glucosamine-6-phosphate deaminase-encoding gene, compared to the naturally occurring gene, due to partial or total deletion/mutation in the glucosamine-6-phosphate deaminase-encoding nucleic acid sequence can be expressed herein as "reduction" or "deletion".
- To induce no or less expression of glucosamine-6-phosphate deaminase gene, for example, a mutation may occur in the promoter and regulatory regions located upstream of the structure gene. A regulatory cassette attached in upstream of the structural gene may also execute the same functions. The promoter may be modified to reduce the expression, or gene translation may be regulated by reduced m-RNA stability so as to reduce the expression. In addition, the activity of glucosamine-6-phosphate deaminase may be reduced or deleted by replacement of a part or the whole of the gene with a deleted or mutated fragment by site-specific recombination DNA technology. However, it is obvious to those skilled in the art that no or less expression of the gene may be achieved by a variety of methods well known in the art, in addition to these methods.
- As used herein, the term "ability to produce N-acetyl glucosamine" means that the microorganism of the genus Corynebacterium of the present invention has an ability to produce and accumulate N-acetyl glucosamine in the media in which it is cultured. As used herein, the term "ability to produce glucosamine" refers to an ability to produce glucosamine from a material produced by microbial fermentation, and refers to an ability of the microorganism of the genus Corynebacterium of the present invention, that produces and accumulates glucosamine by deacetylation of N-acetyl glucosamine accumulated in the culture media into glucosamine, according to various methods known in the art.
- As used herein, the term "microorganism having an ability to produce N-acetyl glucosamine and/or glucosamine" is a microorganism belonging to the genus Corynebacterium. Preferably, the microorganism is Corynebacterium glutamicum (e.g., ATCC13032), Corynebacterium ammoniagenes (e.g., ATCC 6872), Brevibacterium lactofermentum (e.g., ATCC13869), Brevibacterium flavum (e.g., ATCC14067), Corynebacterium thermoaminogenes (e.g., FERM-BP1539), Corynebacterium efficiens (e.g., C.efficiens str. YS-314) or the like, but is not limited thereto. More preferably, the microorganism is Corynebacterium glutamicum, and even more preferably, Corynebacterium glutamicum CJNAG1 deposited at KCCM (Korean Culture Center of Microorganisms, Eulim Buld., 361-221, Hongje-1-Dong, Seodaemun-Ku, Seoul, 120-861, Korea) on September 29, 2008 with the Accession No: KCCM10967P.
- In another aspect, the present invention relates to a method for producing N-acetyl glucosamine or glucosamine which comprises culturing the microorganism of the genus Corynebacterium having an ability to produce N-acetyl glucosamine.
- In particular, the present invention relates to a method for producing N-acetyl glucosamine or glucosamine, comprising the steps of (a) culturing the microorganisms of the genus Corynebacterium having an ability to produce N-acetyl glucosamine of the present invention and (b) collecting N-acetyl glucosamine or glucosamine produced in the culturing step.
- The above culture of the present invention can be performed by a proper medium and conditions known to those in the art. It is well understood by those in the art that the culture method can be used by easily adjusting the same, according to the selected strain. For example, the culture methods include, but are not limited to batch, continuous culture and fed-batch. A variety of culture methods are described in, for example, the following reference: "Biochemical Engineering" by James M. Lee, Prentice-Hall International Editions, pp 138-176. The medium used in the culture has to meet the culture conditions for a specific strain.
- The medium used in the present invention contains glucose as a main carbon source, and the medium may contain a proper amount of various carbon sources. The nitrogen source to be used is exemplified by such organic nitrogen sources as peptone, yeast extract, gravy, malt extract, corn steep liquor and bean flour and such inorganic nitrogen source as urea, ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate. These nitrogen sources may be used either alone or in combinations. The medium herein can additionally include potassium dihydrogen phosphate, dipotassium hydrogen phosphate and corresponding sodium-containing salts as a phosphate source. The medium also can include a metal salt such as magnesium sulfate or iron sulfate. In addition, amino acids, vitamins and proper precursors can be added. These mediums or precursors can be added to the culture by batch-type or continuous type.
- During cultivation, ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, and sulfuric acid may be properly added so as to adjust the pH of the cultures. Defoaming agents such as fatty acid polyglycol ester may be properly added so as to reduce the formation of foams in cultures. To maintain the cultures in aerobic states, oxygen or oxygen-containing gas may be injected into the cultures. To maintain the cultures in anaerobic and microaerobic states, no gas may be injected or nitrogen, hydrogen, or carbon dioxide gas may be injected into the cultures. The cultures are maintained at 30 to 37°C, and preferably at 35 to 37ºC. The cultivation may be continued until a desired amount of the desired material is obtained, and preferably for 10 to 160 hrs.
- The step of collecting and/or recovering N-acetyl glucosamine or glucosamine produced in the cultivation step of the present invention may be performed by a proper method known in the art, depending on the culturing procedures, for example, batch type, continuous type or fed-batch type, so as to collect the desired N-acetyl glucosamine or glucosamine from the culture medium.
- In addition, the present invention may further include the step of converting the collected N-acetyl glucosamine into glucosamine by deacetylation. It will be apparent to those skilled in the art that the conversion may be performed by the method widely known in the art (e.g., Novikov V.Y. et al. Russ. J. Appl. Chem. 1997:1467-1470).
- Hereinafter, the present invention will be described in more detail with reference to Examples. However, these Examples are for illustrative purposes only, and the invention is not intended to be limited by these Examples.
- To prevent utilization of N-acetyl glucosamine-6-phosphate by the wild-type Corynebacterium glutamicum (ATCC13102), N-acetyl glucosamine-6-phosphate deaminase-encoding nagA1 (NCgl2556, SEQ ID NO. 1) which utilizes N-acetyl glucosamine-6-phosphate as a substrate was inactivated.
- The inactivation may be performed by various methods such as gene deletion or introduction of additional sequence, and in the present Example, a stop codon was inserted into the ORF (open reading frame) of the nagA1 gene to induce inactivation of gene translation.
- Specifically, a genomic DNA was isolated from Corynebacterium glutamicum (ATCC13102), and PCR was performed using the genomic DNA as a template and primers of SEQ ID NOs. 2 and 3 so as to obtain N-acetyl glucosamine-6-phosphate deaminase-encoding gene (nagA1: NCg12556).
- Each sequence of the primers used to amplify nags1 gene is as follows.
- SEQ ID NO. 2 (nagA1 - 5)
5' - GGAATTCATGGCAGAAGTGGTGCATTATCAAG - 3' - SEQ ID NO. 3 (nagA1 - 3)
5' - GCTCTAGAGATGATGTCCATGGTCGGACTCC - 3' - To construct an N-acetyl glucosamine-6-phosphate deaminase mutant having a stop codon in ORF using the wild-type N-acetyl glucosamine-6-phosphate deaminase gene, additional primers (SEQ ID NOs. 4 and 5) were prepared to insert a stop codon between isoleucine at position 196 and alanine at position 197.
- Specifically, PCR was performed using the wild-type nagA1 obtained by PCR as a template and each of the primers of SEQ ID NOs. 2 and 4 and SEQ ID NOs. 3 and 5. Two final products were a part of the nagA1, and thus had a half size thereof. These two products were simultaneously used as a template and the primers of SEQ ID NOs. 2 and 3 were used to perform PCR again. Through this procedure, genes encoding inactivated N-acetyl glucosamine 6-phosphate deaminase mutants were obtained. The inactivated nagA1 gene fragment was introduced into a chromosomal DNA substitution vector pDZ using the restriction enzymes, EcoRI (New England Biolabs, Beverly, MA) and XbaI (New England Biolabs, Beverly, MA) by the molecular biology technique disclosed in Korean Patent Publication No.
2008-0025355 FIG. 2 ). - SEQ ID NO. 4 (nagA1ST - 5)
5' - GTGCCCGAAGGAAGCTTAAATGATGTGGTGCGC - 3' - SEQ ID NO. 5 (nagA1ST 3)
5' - GCGCACCACATCATTTAAGCTTCCTTCGGGCAC - 3' - To transform the wild-type Corynebacterium glutamicum (ATCC13102) strain with the constructed pDZ-nagA1ST vector, a stop codon was inserted into the ORF of nagA1 gene on the chromosome by secondary crossover, as described in Korean Patent Publication No.
2008-0025355 - In order to produce N-acetyl glucosamine, a vector expressing glucosamine-6-phosphate acetyltransferase, which is an enzyme producing N-acetyl glucosamine-6-phosphate using glucosamine-6-phosphate as a substrate, was constructed. For industrial application, a constitutive promoter was used to construct the vector so as to ensure constitutive expression of the enzyme during cell growth. The enzyme used for the expression was GNA1, the known glucosamine-6-phosphate acetyltransferase gene of yeast Saccharomyces cerevisiae.
- For constitutive expression of the enzyme, an EFTU promoter (Judith B. et al. Appl Environ Microbiol. 2005:8587-8596.) that is known as a constitutive promoter in Corynebacterium glutamicum was used. PCR was performed using the chromosome isolated from Corynebacterium glutamicum as a template and the primers of SEQ ID NOs. 6 and 7 to obtain the EFTU promoter (SEQ ID NO. 8). The obtained PCR product of EFTU promoter was introduced into a pECCG1117 vector (Biotechnology letters vol 13, No.10, p.721-726(1991) or Korean Patent Publication No.
92-7401 FIG. 3 ). - Each sequence of the primers used to amplify the EFTU promoter and GNA1 gene is as follows.
- SEQ ID NO. 6 (EFTU - 5)
5' - GACTAGTATGTTCGGTTACGTCGGTGACCTTC - 3' - SEQ ID NO. 7 (EFTU - 3)
5' - CCCAAGCTTCTATTTTCTAATTTGCATTTCCACGCCTGC - 3' - SEQ ID NO. 9 (GNA1 - 5)
5' - GGAATTCCATATGAGCTTACCCGATGGATTTTATATAAGG - 3' - SEQ ID NO. 10 (GNA1 - 3)
5' - GCTCTAGACTATTTTCTAATTTGCATTTCCACGCC - 3' - An inducible expression system of Corynebacterium glutamicum was constructed to compare with the constitutive expression system of Corynebacterium glutamicum of Example 3.
- Specifically, PCR was performed using the chromosome isolated from Saccharomyces cerevisiae as a template and the primers of SEQ ID NOs. 9 and 10 to obtain GNA1. The obtained GNA1 was introduced into a pVWEx2 vector known as an inducible expression system in Corynebacterium glutamicum (Appl. Microbiol. Biotechnol. 2007. 76:545-552) using PstI (New England Biolabs, Beverly, MA) and XbaI (New England Biolabs, Beverly, MA) to construct a pVWEx2-GNA1 vector (
FIG. 4 ). A lacIq-Ptac promoter was used for the inducible expression. Each sequence of the used primers is as follows. - SEQ ID NO. 12 (Vw2-GNA1 - 5)
5' - AACTGCAGATGAGCTTACCCGATGGATTTTATATAAGG - 3' - SEQ ID NO. 13 (Vw2-GNA1 - 3)
5' - GCTCTAGACTATTTTCTAATTTGCATTTCCACGCCTGC - 3' - In order to produce N-acetyl glucosamine using Corynebacterium glutamicum, glucosamine-6-phosphate acetyltransferase (GNA1) was introduced into the mutant CJNAGKO which has a stop codon in the N-acetyl glucosamine-6-phosphate deaminase (nagA1) ORF on the chromosome. That is, each of p117-PEFTU-GNA1 and pVWEx2-GNA1 constructed in Examples 3 and 4 was transformed into CJNAGKO to prepare strains that have a glucosamine-6-phosphate acetyltransferase (GNA1) activity without N-acetyl glucosamine-6-phosphate deaminase activity. The prepared strains are designated CJNAG1 (KCCM10967P) and CJNAG2, respectively (Table 1).
- In order to test whether the prepared strains produce N-acetyl glucosamine, a strain having inactivated N-acetyl glucosamine-6-phosphate deaminase only (Control 2) and a strain having amplified glucosamine-6-phosphate acetyltransferase only (Control 3) were prepared and used as control groups. The wild-type Corynebacterium glutamicum was also used as a control group (Control 1). Finally, the production of N-acetyl glucosamine was analyzed (Table 1).
- The medium composition and culture method were as follows. 5 ml of seed medium (5 g of trypton, 2.5 g of yeast extract, 5 g of NaCl, 18.5 g of Brain heart infusion in 500 ml of distilled water, and 91 g of sorbitol in 500 ml of distilled water, each of them were sterilized at high pressure and high temperature, and then mixed with each other) was put in test tubes, and then test strains were inoculated thereto, followed by incubation at 30°C for 12 hrs. 20 ml of the culture media (based on 1 L of distilled water, 90 g of glucose sterilized separately, 40 g of (NH4)2SO4, 2.5 g of Soy Protein, 5 g of Corn Steep Solids, 3 g of urea, 1 g of KH2PO4, 0.5 g of MgSO4 7H2O, 100 µg of biotin, 1000 µg of thiamine hydrochloride, 2000 µg of calcium pantothenate, 3000 µg of nicotinamide, 30 g of CaCO3 sterilized separately) was aliquoted in 250 ml Erlenmeyer flasks, and then 200 ul of seed culture medium was inoculated thereto, followed by fermentation at 30°C for 42 hrs. In particular, 100 uM of IPTG was added to 'Control 3' and 'CJNAG2' that were transformed with pVWEx2-GNA1, when optical density (OD) of the cells was 10 at 600 nm. Each strain was tested using three flasks, and the average number of cells and N-acetyl glucosamine concentration were measured. The fermentation results showed that N-acetyl glucosamine was produced at a concentration of approximately 1.0 g/L or more, irrespective of constitutive and inducible expression (Table 1). It can be seen that the constitutive expression system can be additionally used in the Corynebacterium, whereas the known NAG production by the use of E.coli should adopt only the inducible expression system that allows for the separation of the growth and production phase.
[Table 1] Strain Cell OD (Abs. 600 nm) N-acetyl glucosamine (mg/L) Control 1Wild-type strain 87.2 42 Control 2 nagA1-inactivated strain 81.1 44 Control 3 GNA1 inducible expression strain 82.3 50 CJNAG1 nagA1-inactivated and GNA1 constitutive expression strain 88.1 1,241 CJNAG2 nagA1-inactivated and GNA1 inducible expression strain 83.3 1,108 - Glucosamine can be produced from deacetylation of the produced N-acetyl glucosamine by acid treatment, which can be performed by the known method described in Novikov V.Y. et al. (Russ. J. Appl. Chem. 1997:1467-1470), indicating that the production of N-acetyl glucosamine easily allows additional production of glucosamine.
- Various modifications or variations of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications and variations are intended to fall within the scope of the claims appended hereto.
- According to the present invention, a microorganism of the genus Corynebacterium having an ability to produce N-acetyl glucosamine can be developed, and thus N-acetyl glucosamine or glucosamine is produced using the microorganism, thereby realizing mass production of N-acetyl glucosamine and glucosamine without the risk of allergic reactions. Further, it is industrially applicable, since health foods and therapeutic materials can be safely produced, and crucial enzymes can be constitutively expressed.
Claims (9)
- A microorganism of the genus Corynebacterium having an ability to produce N-acetyl glucosamine, wherein the microorganism has a glucosamine-6-phosphate acetyltransferase activity and a reduced or deleted glucosamine-6-phosphate deaminase activity.
- The microorganism of the genus Corynebacterium according to claim 1, wherein the glucosamine-6-phosphate acetyltransferase is encoded by a nucleic acid sequence of SEQ ID NO. 11.
- The microorganism of the genus Corynebacterium according to claim 1, wherein the glucosamine-6-phosphate acetyltransferase is inducibly or constitutively expressed.
- The microorganism of the genus Corynebacterium according to claim 3, wherein the constitutive expression is driven by an EFTU promoter.
- The microorganism of the genus Corynebacterium according to claim 3, wherein the inducible expression is driven by a lacIq-Ptac promoter.
- The microorganism of the genus Corynebacterium according to claim 1, wherein the microorganism is Corynebacterium glutamicum.
- The microorganism of the genus Corynebacterium according to claim 1, wherein the microorganism is Corynebacterium glutamicum CJNAG1 (KCCM10967P).
- A method for producing N-acetyl glucosamine or glucosamine, comprising the steps of:(a) culturing the microorganisms of the genus Corynebacterium having an ability to produce N-acetyl glucosamine of any one of claims 1 to 7, and(b) collecting N-acetyl glucosamine or glucosamine produced in the culturing step.
- The method according to claim 8, wherein N-acetyl glucosamine collected in step (b) is deacetylated to produce glucosamine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20080102633 | 2008-10-20 | ||
PCT/KR2009/006063 WO2010047516A2 (en) | 2008-10-20 | 2009-10-20 | Corynebacterium genus microorganism with ability to produce n-acetyl glucosamine and method for producing n-acetyl glucosamine or glucosamine using same |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2348101A2 true EP2348101A2 (en) | 2011-07-27 |
EP2348101A4 EP2348101A4 (en) | 2013-01-02 |
EP2348101B1 EP2348101B1 (en) | 2016-05-04 |
Family
ID=42119826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09822192.2A Active EP2348101B1 (en) | 2008-10-20 | 2009-10-20 | Corynebacterium genus microorganism having ability to produce n-acetyl glucosamine and method for producing n-acetyl glucosamine or glucosamine using same |
Country Status (7)
Country | Link |
---|---|
US (1) | US9005957B2 (en) |
EP (1) | EP2348101B1 (en) |
JP (1) | JP5677963B2 (en) |
KR (1) | KR101102720B1 (en) |
CN (1) | CN103429731B (en) |
ES (1) | ES2584531T3 (en) |
WO (1) | WO2010047516A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013128274A3 (en) * | 2012-03-02 | 2014-02-20 | Asis Datta | Recombinant microorganisms and uses thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105695350B (en) * | 2016-03-23 | 2020-02-07 | 西藏天虹科技股份有限责任公司 | Saccharomyces cerevisiae and method for producing glucosamine by using saccharomyces cerevisiae |
KR101912359B1 (en) * | 2016-05-18 | 2018-10-26 | 고려대학교 산학협력단 | Microorganism Having Improved N-acetylglucosamine Producing Capability by Modulating Glycolytic Flux |
US10724015B2 (en) | 2016-05-18 | 2020-07-28 | Korea University Research And Business Foundation | Microorganism having improved ability to produce N-acetylglucosamine as a result of modulating glycolytic flux |
KR102254635B1 (en) * | 2021-01-27 | 2021-05-21 | 씨제이제일제당 주식회사 | Novel glucosamine-6-phosphate deaminase variant and a method for producing L-glutamic acid using the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004003175A2 (en) * | 2002-07-01 | 2004-01-08 | Arkion Life Sciences Llc | Process and materials for production of glucosamine and n-acetylglucosamine |
US20070269872A1 (en) * | 2006-05-19 | 2007-11-22 | Agribioindustry Inc. | Recombinant coryneform bacterium and method for producing diodegradable polyester |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR920007401B1 (en) | 1990-06-21 | 1992-08-31 | 제일제당 주식회사 | Novel shuttle vector |
US20020160459A1 (en) | 1997-01-14 | 2002-10-31 | Alan Berry | Process for production of n-glucosamine |
US6372457B1 (en) * | 1997-01-14 | 2002-04-16 | Arkion Life Sciences Llc | Process and materials for production of glucosamine |
US20020115639A1 (en) | 2001-02-16 | 2002-08-22 | Weiyu Fan | Glucosamine and method of making glucosamine from microbial blomass |
CA2465066A1 (en) * | 2001-10-26 | 2003-05-01 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing beta 1,3-n-acetylglucosaminyl transferase and n-acetylglucosamine-containing complex carbohydrate |
US20050042735A1 (en) | 2003-04-11 | 2005-02-24 | Ming-De Deng | Metabolic engineering for enhanced production of chitin and chitosan in microorganisms |
DE10359594A1 (en) * | 2003-12-18 | 2005-07-28 | Basf Ag | PEF TU-expression units |
JP2008245633A (en) * | 2006-05-19 | 2008-10-16 | Agri Bioindustry:Kk | Recombinant coryneform bacterium and method for producing biodegradable polyester |
EP3170889A1 (en) * | 2006-09-15 | 2017-05-24 | CJ Cheiljedang Corporation | A corynebacteria having enhanced l-lysine productivity and a method of producing l-lysine using the same |
-
2009
- 2009-10-20 KR KR1020090099986A patent/KR101102720B1/en active IP Right Grant
- 2009-10-20 JP JP2011533101A patent/JP5677963B2/en active Active
- 2009-10-20 EP EP09822192.2A patent/EP2348101B1/en active Active
- 2009-10-20 US US13/125,181 patent/US9005957B2/en active Active
- 2009-10-20 WO PCT/KR2009/006063 patent/WO2010047516A2/en active Application Filing
- 2009-10-20 CN CN200980145486.5A patent/CN103429731B/en active Active
- 2009-10-20 ES ES09822192.2T patent/ES2584531T3/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004003175A2 (en) * | 2002-07-01 | 2004-01-08 | Arkion Life Sciences Llc | Process and materials for production of glucosamine and n-acetylglucosamine |
US20070269872A1 (en) * | 2006-05-19 | 2007-11-22 | Agribioindustry Inc. | Recombinant coryneform bacterium and method for producing diodegradable polyester |
Non-Patent Citations (4)
Title |
---|
DENG M D ET AL: "Metabolic engineering of Escherichia coli for industrial production of glucosamine and N-acetylglucosamine", METABOLIC ENGINEERING, ACADEMIC PRESS, US, vol. 7, no. 3, 1 May 2005 (2005-05-01), pages 201-214, XP004879515, ISSN: 1096-7176, DOI: 10.1016/J.YMBEN.2005.02.001 * |
JUDITH BECKER ET AL: "Amplified Expression of Fructose 1,6-Bisphosphatase in Corynebacterium glutamicum Increases In Vivo Flux through the Pentose Phosphate Pathway and Lysine Production on Different Carbon Sources", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 71, no. 12, 1 December 2005 (2005-12-01), pages 8587-8596, XP008148992, ISSN: 0099-2240, DOI: 10.1128/AEM.71.12.8587-8596.2005 * |
See also references of WO2010047516A2 * |
SRIVASTAVA P ET AL: "Gene expression systems in corynebacteria", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, vol. 40, no. 2, 1 April 2005 (2005-04-01), pages 221-229, XP004781372, ISSN: 1046-5928, DOI: 10.1016/J.PEP.2004.06.017 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013128274A3 (en) * | 2012-03-02 | 2014-02-20 | Asis Datta | Recombinant microorganisms and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2012505667A (en) | 2012-03-08 |
CN103429731A (en) | 2013-12-04 |
CN103429731B (en) | 2017-12-26 |
EP2348101A4 (en) | 2013-01-02 |
US9005957B2 (en) | 2015-04-14 |
WO2010047516A3 (en) | 2010-09-10 |
KR20100044129A (en) | 2010-04-29 |
JP5677963B2 (en) | 2015-02-25 |
KR101102720B1 (en) | 2012-01-05 |
WO2010047516A2 (en) | 2010-04-29 |
EP2348101B1 (en) | 2016-05-04 |
US20110250647A1 (en) | 2011-10-13 |
ES2584531T3 (en) | 2016-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7488937B2 (en) | Improved methods for the production of fucosylated oligosaccharides | |
US11118205B2 (en) | Method for producing n-acetyl-d-glucosamine and/or d-glucosamine salt by microbial fermentation | |
RU2732228C1 (en) | Novel promoter and method of producing purine nucleotides using same | |
JP7033665B2 (en) | Corynebacterium microorganisms that produce purine nucleotides and methods for producing purine nucleotides using them. | |
JP5254353B2 (en) | 2-deoxy-siro-inosose (DOI) producing bacterium and 2-deoxy-siro-inosose (DOI) producing method using the same | |
CN110249054A (en) | The method for generating the microorganism of IMP and generating IMP using it | |
CN101960005B (en) | The production method of 5'-GMP | |
CN1226931A (en) | Escherichia coli strains and preparation thereof and use thereof in fermentation process for production of L-threonine | |
CN105392880A (en) | Microorganism producing o-acetyl homoserine, and method for producing O-acetyl homoserine by using microorganism | |
US9005957B2 (en) | Corynebacterium genus microorganism having ability to produce N-acetyl glucosamine and method for producing N-acetyl glucosamine or glucosamine using the same | |
JP6646075B2 (en) | Microorganism producing L-lysine and method for producing L-lysine using the same | |
CA2633357A1 (en) | Method for producing optically active compound | |
JP2001136982A (en) | Method for producing n-acetylneuraminic acid | |
KR20130101030A (en) | Improved glycolic acid fermentative production with a modified microorganism | |
EP2295546B1 (en) | Method for producing 5'-guanylic acid | |
WO2017174036A1 (en) | Method for producing n-acetyl-d-glucosamine and/or d-glucosamine hydrochloride by microbial fermentation | |
WO2003072783A1 (en) | Process for producing n-acetylneuraminic acid | |
TW201016849A (en) | Method for producing lactate using plant-derived materail and lactate-producing bacteria | |
KR20230004466A (en) | Process for producing sulfated polysaccharide and process for producing PAPS | |
WO2017174040A1 (en) | Method for producing n-acetyl-d-glucosamine and/or d-glucosamine salt by microbial fermentation | |
WO2017174037A1 (en) | Method for producing n-acetyl-d-glucosamine and/or d-glucosamine salt by microbial fermentation | |
WO2017174039A1 (en) | Method for producing n-acetyl-d-glucosamine and/or d-glucosamine salt by means of microbial fermentation | |
WO2017174038A1 (en) | Method for producing n-acetyl-d-glucosamine and/or d-glucosamine salt by microbial fermentation | |
JP7462776B2 (en) | Microorganisms with enhanced L-branched-chain amino acid production ability and method for producing L-branched-chain amino acids using the same | |
Le et al. | Evaluation of the growth of\(\textit {Vibrio natriegens}\) strains in a medium containing chitin derivatives and shrimp shell hydrolysate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110421 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602009038496 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C12N0001200000 Ipc: C12N0001210000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20121129 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 1/21 20060101AFI20121123BHEP Ipc: C12P 19/26 20060101ALI20121123BHEP Ipc: C12N 9/10 20060101ALI20121123BHEP Ipc: C12N 9/78 20060101ALI20121123BHEP |
|
17Q | First examination report despatched |
Effective date: 20131016 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160104 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 796928 Country of ref document: AT Kind code of ref document: T Effective date: 20160515 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602009038496 Country of ref document: DE Representative=s name: VOSSIUS & PARTNER PATENTANWAELTE RECHTSANWAELT, DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602009038496 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20160504 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2584531 Country of ref document: ES Kind code of ref document: T3 Effective date: 20160928 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160804 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 796928 Country of ref document: AT Kind code of ref document: T Effective date: 20160504 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160905 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160805 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602009038496 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20170207 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20170630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161102 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161020 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161020 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20091020 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230606 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230821 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20231110 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20230822 Year of fee payment: 15 |